Journal Overview

Oncologie

ISSN: 1292-3818 (Print)

ISSN: 1765-2839 (Online)

About this journal：

Oncologie is an open-access, peer-reviewed journal providing a forum for high-quality research and clinical advances in oncology. It welcomes submissions from researchers, clinicians, and healthcare professionals worldwide, supporting knowledge exchange, international collaboration, and the advancement of cancer care. The journal is published bimonthly in English.

Aims & Scope：

Oncologie publishes original research, reviews, case reports, and other contributions across all aspects of tumor and cancer research and treatment, including molecular and cellular oncology, cancer prevention, early detection and screening, diagnosis, and clinical management of neoplastic diseases.

The journal welcomes both clinical and preclinical studies, including clinical trials, pharmacology, molecular alterations, and biomarkers predicting treatment response or resistance, as well as in vitro and in vivo studies of tumor biology, progression, metastasis, and therapy resistance. Research in precision oncology, personalized medicine, and molecular oncology is particularly encouraged, with an emphasis on translational research bridging laboratory discoveries with clinical applications.

Research topics may include, but are not limited to:

Cancer genetics and genomics

Omics and bioinformatics in cancer research

Cancer cytology and pathology

Immunology, immuno-oncology, and immunotherapy

Chemotherapy and radiotherapy

Precision oncology and personalized medicine

Solid tumors and surgical oncology

Gynecologic and hematologic oncology

Pediatric oncology

Palliative and supportive care, survivorship, and quality-of-life research

Oncology nursing and psycho-oncology

Clinical trial design

Cancer epidemiology

Methodological studies, including modern statistical approaches and meta-analyses

Audience:

Oncologie reaches clinicians, researchers, and healthcare professionals in oncology, as well as data scientists, educators, and students in related biomedical disciplines.

Publication Frequency

Bi-monthly

IF

Current Impact Factor: 2.5 (2024)

5-Year Impact Factor: 1.9

Citescore

2.4 (2024)

Acceptance rate

20% (2025)

Speed

Submission to first post-review decision (average time): 32 days (2025)

Submission to acceptance (average time): 87 days (2025)

Ownership

The journal is owned and editorially managed by Tech Science Press. It is published by De Gruyter on behalf of Tech Science Press.

Society Collaborations

Malaysian Association for Cancer Research (MACR), Malaysia

La Société Française de Chirurgie Oncologique (SFCO), France.

la Fédération Française des Oncologues Médicaux (FFOM), France.

l’Association Francophone pour les Soins Oncologiques de Support (AFSOS), France.

Open Access

All articles published will be Gold open access under the terms and conditions of the Creative Commons Attribution License 4.0 (CC-BY 4.0), and are made freely and permanently accessible online from the date of publication. For further information, please refer to the Open Access Policy.

Archiving

All journals published by TSP are archived in Portico, which provides permanent digital archiving for scholarly journals.

Ethics Statement

TSP takes the responsibility to enforce a rigorous peer-review together with strict ethical policies and standards to ensure adding the highest quality scientific works to the field of scholarly publication. TSP takes such publishing ethics issues very seriously on every level. Our staff are trained to identify and report any irregularities. Our editors follow Guidelines of the Committee on Publication Ethics (COPE), and proceed with a zero tolerance policy for ethical violations, including plagiarism, data falsification and authorship misconduct. To confirm the originality of all submitted manuscripts, we use iThenticate for similarity checks against prior publications.